-
Cancer Chemotherapy and Pharmacology 1987Medroxyprogesterone acetate (MAP) plasma pharmacokinetics was followed up in a total of 30 New Zealand rabbits after i.v. administration (0.1, 0.5, and 1.0 mg/kg) of... (Comparative Study)
Comparative Study
Medroxyprogesterone acetate (MAP) plasma pharmacokinetics was followed up in a total of 30 New Zealand rabbits after i.v. administration (0.1, 0.5, and 1.0 mg/kg) of either an aqueous suspension or a homogeneous solution of the drug in dimethylsulphoxide (DMSO). A well-defined triphasic decay of MAP plasma levels was noticeable in the animals treated with DMSO solutions. A delayed concentration peak was often present when aqueous suspensions were used, so if is not feasible to fit the experiment with simple polyexponential equations. Model-independent pharmacokinetic analysis (statistical moment theory) revealed a significant dependence of plasma clearance and mean residence time on the dose administered in both conditions.
Topics: Animals; Chromatography, Gas; Dimethyl Sulfoxide; Female; Kinetics; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Rabbits; Solutions; Suspensions
PubMed: 2954713
DOI: 10.1007/BF00261479 -
Lancet (London, England) Feb 1991
Topics: Acute Disease; Adult; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Pain; Pelvis; Varicose Veins
PubMed: 1671429
DOI: No ID Found -
The Journal of Clinical Endocrinology... Feb 1991
Topics: Estrogens, Conjugated (USP); Female; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Premenstrual Syndrome
PubMed: 1846867
DOI: 10.1210/jcem-72-2-250 -
The Tohoku Journal of Experimental... Jun 1990A 70-year-old man having severe ischemic heart diseases developed bilateral, duplicate lung cancer of large cell and squamous cell types. Chemoimmunotherapy consisting...
A 70-year-old man having severe ischemic heart diseases developed bilateral, duplicate lung cancer of large cell and squamous cell types. Chemoimmunotherapy consisting of carmofur, picibanil inhalation, i.m. sizofilan, and peroral bestatin was started, and 3 months later, peroral medroxyprogesterone acetate was added. The tumor regressed, and the patient survived more than 34 months. This type of nonaggressive regimen may thus be useful for tumors other than adenocarcinomas, too.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Humans; Lung Neoplasms; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Radiography
PubMed: 2148230
DOI: 10.1620/tjem.161.153 -
Lancet (London, England) Oct 1991
Topics: Adolescent; Adult; Breast Neoplasms; Contraceptive Agents, Female; Delayed-Action Preparations; Female; Humans; Life Expectancy; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged
PubMed: 1681281
DOI: 10.1016/0140-6736(91)91804-4 -
Chemioterapia : International Journal... Dec 1987Twenty-six postmenopausal consecutive patients with advanced breast cancer were treated with very high medroxyprogesterone acetate doses (4000 mg/day orally for 30 days...
Twenty-six postmenopausal consecutive patients with advanced breast cancer were treated with very high medroxyprogesterone acetate doses (4000 mg/day orally for 30 days and then 3000 mg/day orally until progression or intolerance). The dominant metastatic lesion was bone in 13 patients, soft tissue in 3 patients and viscera in 10 patients (C.I. = V/ST + 0 = 0.62). An objective partial remission was achieved in 16 pts (61%), no change in 8 (31%), progression in 2 (8%). The median duration of objective remission was 7.5+ months with a median survival of 14.5+ months in responders. Toxicity was minor and only two patients discontinued the treatment because of side-effects. These results confirm the utility of medroxyprogesterone acetate at very high doses in these patients and the feasibility of this kind of dose.
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Middle Aged; Remission Induction
PubMed: 2963702
DOI: No ID Found -
Gan To Kagaku Ryoho. Cancer &... Aug 1987
Review
Topics: Breast Neoplasms; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate
PubMed: 2956928
DOI: No ID Found -
American Journal of Obstetrics and... Apr 1989Medroxyprogesterone acetate (Provera) is a drug that is commonly given to young women with cancer during chemotherapy and radiation to control heavy bleeding associated...
Medroxyprogesterone acetate (Provera) is a drug that is commonly given to young women with cancer during chemotherapy and radiation to control heavy bleeding associated with anovulation. Because hypothalamic-pituitary-ovarian suppression has been associated with ovarian protection from the effects of chemotherapy and medroxyprogesterone acetate has been identified as a radiosensitizing agent, we explored the effects of medroxyprogesterone acetate on a rat model with known radiation injury characteristics. Sprague-Dawley rats were treated with medroxyprogesterone acetate or vehicle from day 22 to day 37 of life and were either irradiated or sham-irradiated on day 30 of life and then killed on day 44. Radiation with medroxyprogesterone acetate administration produced a greater loss in preantral and healthy control follicles than in control follicles. No suppression of luteinizing hormone or follicle-stimulating hormone had occurred by day 30 but ovarian glutathione content was reduced. These findings indicate that the administration of medroxyprogesterone acetate with radiotherapy may enhance ovarian injury.
Topics: Animals; Estrus; Female; Glutathione; Gonadotropins; Medroxyprogesterone; Medroxyprogesterone Acetate; Organ Size; Ovary; Radiation Tolerance; Rats; Rats, Inbred Strains
PubMed: 2523668
DOI: 10.1016/0002-9378(89)90322-0 -
Chest Dec 1986We studied the effects of medroxyprogesterone acetate, a respiratory stimulant, on the incidence and duration of episodes of apnea and disordered breathing in 13...
We studied the effects of medroxyprogesterone acetate, a respiratory stimulant, on the incidence and duration of episodes of apnea and disordered breathing in 13 nonhypercapnic men with obstructive sleep apnea. Nocturnal polysomnography was done before and after four weeks of treatment with medroxyprogesterone acetate (60 mg/day) and one week after cessation of treatment. There were no significant (p less than 0.05) differences in the mean frequency of apneic episodes per hour of sleep before (31.3 +/- 5.7 [+/- SE]), during (26.8 +/- 6.6), or after (23.6 +/- 7.0) treatment, or in the mean number of disordered breathing episodes per hour of sleep before (19.4 +/- 5.6), during (21.4 +/- 5.8), or after (23.1 +/- 6.3) the period of treatment. Medroxyprogesterone did not alter significantly the total time of apnea or the total time for disordered breathing, expressed as percentages of total sleep time. Arterial oxygen desaturation during apnea and disordered breathing did not change with treatment. Medroxyprogesterone increased the minute ventilation and occlusion pressure responses to hypercapnia measured in the awake state; however, the results of this study demonstrate that medroxyprogesterone does not improve the breathing disorders during sleep in the nonhypercapnic patient with obstructive sleep apnea.
Topics: Adult; Anthropometry; Humans; Male; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Sleep Apnea Syndromes; Sleep, REM; Tidal Volume; Transducers, Pressure; Vital Capacity
PubMed: 2946559
DOI: 10.1378/chest.90.6.815 -
The New Zealand Medical Journal May 1990
Topics: Adult; Breast Neoplasms; Contraceptive Agents, Female; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Risk Factors
PubMed: 2140436
DOI: No ID Found